Author's reply

BMJ 1995; 310 doi: 10.1136/bmj.310.6989.1268c (Published 13 May 1995)
Cite this as: BMJ 1995;310:1268.4

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Hank Balfour
  1. Professor Box 437 UMHC, 15-144 PWB Harvard Street at East River Parkway, Minneapolis, MN 55455, USA

    EDITOR,—Treatment of an otherwise normal child with chickenpox is probably as controversial in the United States as it is in Britain. Clearly, costbenefit considerations are a—if not the—major issue. Acyclovir shortens the course of chickenpox by 25% to 33% overall. Of more importance is that the …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL